Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Core One Labs Inc (CSE: COOL )

0.1050 -0.0050 (-4.55%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 154,156
Open 0.1050
Bid (Size) 0.1050 (199,500)
Ask (Size) 0.1300 (2,500)
Prev. Close 0.1100
Today's Range 0.1050 - 0.1050
52wk Range 0.1000 - 0.6800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Core One Enters into Loan Agreement with Right Season Investments
Via ACCESSWIRE
Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
Via ACCESSWIRE

Performance

YTD
-60.38%
-60.38%
1 Month
-12.50%
-12.50%
3 Month
-41.67%
-41.67%
6 Month
-67.69%
-67.69%
1 Year
-83.06%
-83.06%

More News

Read More
Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
Via ACCESSWIRE
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
Via ACCESSWIRE
Core One Labs' Scientists Successfully Complete Breakthrough First Step in Producing API-Grade DMT
Via ACCESSWIRE
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
Via ACCESSWIRE
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
Via ACCESSWIRE
Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds
Via ACCESSWIRE
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
Via ACCESSWIRE
Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method
Via ACCESSWIRE
Core One in Talks with Multiple Companies to Supply Psilocybin
Via ACCESSWIRE
Core One Labs' GMP Drug Takes Further Steps Toward Commercialization: Initiating Development of Psychedelic Prodrugs with Long-established Compounding Pharmacy
Via ACCESSWIRE
Core One's Awakened Completes Successful Synthetic Production of Psilocin in its GMP Certified Manufacturing Facility
Via ACCESSWIRE
Core One Labs' Akome Signs Contract with University of Barcelona: Initiating Animal Model Studies on Psychedelics Drug Development to Combat a Variety of Neurological Diseases
Via ACCESSWIRE
Core One Labs' Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers
Via ACCESSWIRE
Core One Labs’ Prepares for Commercial Production of API-Grade Psilocybin; Plans Initial Production Run at GMP Facility in January
Via ACCESSWIRE
Core One Labs Takes Next Steps to Prepare for Potential Takeover Opportunities
Via ACCESSWIRE
European University to Fund Core One Labs' Akome Advanced Neurogenesis Stimulation Studies
Via ACCESSWIRE
Core One Labs Nearing GMP Production as Canada’s Province of Alberta Announces Game Changing Legislation
Via ACCESSWIRE
Core One Labs Announces Breakthrough with Proprietary Isolation and Purification Method of Psilocybin from Mushrooms; Prepares Patent Application
Via ACCESSWIRE
Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds
Via ACCESSWIRE
Core One Labs' Akome Move Psychedelic Drug Formulations to Next Stage of Development: Initiating Phase 2 Analysis of Therapeutic Potential
Via ACCESSWIRE
Core One Rolls Out Commercial Sales Strategy for its Revolutionary API Grade Biosynthetic Psilocybin
Via ACCESSWIRE
Core One Labs Engages in Talks With GMP Manufacturing Partner for Commercial Scale Production of Proprietary Biosynthetic Psilocybin
Via ACCESSWIRE
Core One Labs' Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.